isatuximab
Selected indexed studies
- Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (N Engl J Med, 2024) [PMID:38832972]
- Isatuximab. (, 2006) [PMID:32697463]
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. (Lancet, 2021) [PMID:34097854]
_Worker-drafted node — pending editorial review._
Connections
isatuximab is a side effect of
Sources
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. (2021) pubmed
- Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2024) pubmed
- Isatuximab. (2006) pubmed
- Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. (2022) pubmed
- Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. (2024) pubmed
- Isatuximab: Short Chapter. (2012) pubmed
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. (2019) pubmed
- Isatuximab: A Review of Its Use in Multiple Myeloma. (2021) pubmed
- Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions. (2025) pubmed
- Isatuximab for the treatment of relapsed/refractory multiple myeloma. (2020) pubmed